News and Trends 11 Apr 2022 The Top European Biotech Investments in March 2022 As wars and inflation buffet European markets, private biotech companies raised fewer investments in March 2022 than in previous months. The top private rounds went to firms developing cancer treatments and microbiome therapeutics. The first quarter of 2022 has seen a gradual decline of biotech investments in the European space. The total raised by European […] April 11, 2022 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 8 Apr 2022 Epidarex Backs UK Startup Developing Emerging Anti-Inflammatory Drugs The UK-US venture capitalist Epidarex Capital has led an €11M (£9M) funding round raised by the Edinburgh-based Kynos Therapeutics, which aims to develop anti-inflammatory treatments by blocking an emerging metabolic target. Much of the UK’s biotech innovation is concentrated in the so-called Golden Triangle, encompassing the hubs of Cambridge, Oxford, and London. In 2020, Epidarex […] April 8, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 6 Apr 2022 Immunocore Approvals Open Door for TCR Cancer Drugs The EU has followed the FDA in granting market approval to Kimmtrak, the first-ever bispecific drug based on a cancer-hunting protein called a T-cell receptor (TCR). These regulatory wins by the UK firm Immunocore pave the way for other treatments deploying TCRs. TCRs have become a hot topic in immuno-oncology. Many companies are developing cancer […] April 6, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 1 Apr 2022 Europe Shuns Russian Covid-19 Vaccines as Ukraine War Continues In the last two years, Russian Covid-19 vaccine makers had a tough time penetrating the European market with their flagship vaccine, Sputnik V. This year, Russia’s invasion of Ukraine has likely dashed Sputnik V’s chances of reaching Europe anytime soon. Just months after the Covid-19 pandemic began, Russia was the first country to approve a […] April 1, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 23 Mar 2022 Ilya Pharma Paves Way for Bacterial Gene Therapy with €8.5M Funding Cell and gene therapies are taking off in a big way in Europe. As the buzz grows, the Swedish firm Ilya Pharma has raised €8.5M to lay down the foundations of bacterial gene therapies for enterocolitis and diabetic ulcers. Investor interest in cell and gene therapy is ramping up fast around the world, with a […] March 23, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 17 Mar 2022 €80M Series B Establishes European Champion in Radiopharmaceuticals Big European venture capital firms Jeito, Forbion, and Inkef Capital have teamed up to propel the local radiopharmaceutical scene by investing €80M in the Belgian firm Precirix. Europe has a long history of expertise in the development of radiopharmaceutical drugs. One of the pioneers in the field was Advanced Accelerator Applications (AAA) in France. AAA […] March 17, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 15 Mar 2022 Biotech Stocks in “Total Eclipse” as Financial Pressures Mount More than a year after biotech stock indices peaked, the markets are worse than ever. Meanwhile, rumors of an impending wave of opportunistic biotech acquisitions are yet to materialize. In February of last year, biotech stocks across Europe and the US saw the end of a pandemic-fuelled growth spurt. Since then, the stock growth of […] March 15, 2022 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 10 Mar 2022 Emerging Startups Take Aim at Lysosomal Storage Disorders Lysosomal storage disorders such as Niemann-Pick type C have proved difficult to tackle in the biotech industry. With recent funding rounds in the bag, Scenic Biotech and Maze Therapeutics strive to treat these conditions by activating protective genes. Lysosomal storage disorders are inherited conditions caused by mutations in metabolic enzymes found inside our cells, leading […] March 10, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 8 Mar 2022 The Top European Biotech Investments in February 2022 Companies developing lab automation, ophthalmological treatments, and novel foods received Europe’s top biotech investments in February 2022. European and Israeli biotech investments in February 2022 narrowly beat January’s performance. Life sciences companies in these regions bagged 52 private investments and initial public offerings (IPOs), worth €664M in total. Meanwhile, January’s tally was 41 deals totaling […] March 8, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 3 Mar 2022 Europe’s Ophthalmology Scene Stays Hot for Biotech Funding Ophthalmology-focused startups had a record year for venture capital funding in 2021. Impressive Series A rounds and collaborations hint at a continuing upward trend for the field in 2022. Biotech companies researching treatments for ophthalmological conditions experienced a splurge of venture capital (VC) funding in 2021, with the total more than trebling the haul from […] March 3, 2022 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 1 Mar 2022 European Biotech Industry Braces as War Erupts in Ukraine Europe has been blindsided by its biggest war in decades with Russia’s invasion of Ukraine. Amid a raging humanitarian crisis, the biotech industry is preparing for increasing economic uncertainty, cyber threats, and clinical trial disruptions. The invasion of Ukraine by Russian forces last week caused a widespread outcry from the European community. The geopolitical landscape […] March 1, 2022 - 7 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 23 Feb 2022 EU Bioeconomy Fund Bags €300M to Scale up Sustainability Companies The European Circular Bioeconomy Fund has smashed its funding target by raising €300M. The aim is to help sustainability-focused biotechs scale up and usher in a ‘bio-revolution’ in Europe. As European economies grapple with the aftershocks of the Covid-19 pandemic, policymakers have pledged to prioritize sustainability in plans such as the European Green Deal. However, […] February 23, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email